The ITMO trial was undertaken through a contract between Novartis and ITMO group. Novartis provided everolimus and octreotide LAR. We thank Health Publishing and Services Srl for editorial assistance.
Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study
Article first published online: 18 APR 2014
© 2014 American Cancer Society
Volume 120, Issue 16, pages 2457–2463, August 15, 2014
How to Cite
Bajetta, E., Catena, L., Fazio, N., Pusceddu, S., Biondani, P., Blanco, G., Ricci, S., Aieta, M., Pucci, F., Valente, M., Bianco, N., Mauri, C. M. and Spada, F. (2014), Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study. Cancer, 120: 2457–2463. doi: 10.1002/cncr.28726
- Issue published online: 5 AUG 2014
- Article first published online: 18 APR 2014
- Manuscript Accepted: 28 FEB 2014
- Manuscript Revised: 27 FEB 2014
- Manuscript Received: 21 JAN 2014
- neuroendocrine tumor;
- octreotide long-acting repeatable
Preclinical and clinical studies suggest synergistic activity between somatostatin analogues and mammalian target of rapamycin inhibitors. The activity and safety of everolimus was assessed in combination with octreotide long-acting repeatable (LAR) in patients with neuroendocrine tumors (NETs) of gastroenteropancreatic and lung origin.
This was a phase 2, multicenter trial using a Simon's 2-stage minimax design. Treatment-naive patients with advanced well-differentiated NETs of gastroenteropancreatic tract and lung origin received everolimus 10 mg daily, in combination with octreotide LAR 30 mg every 28 days. The primary endpoint was objective response rate (ORR).
A total of 50 patients (median age, 60.5 years) were enrolled. Primary tumor sites were: pancreas (14 patients), lung (11 patients), ileum (9 patients), jejunum and duodenum (2 patients), and unknown (14 patients). Thirteen patients (26%) had carcinoid syndrome. Treatment-related adverse events (AEs) were mostly grade 1 or 2; the only grade 4 AE was mucositis in 1 patient, whereas grade 3 AEs included skin rash in 1 case (2%), stomatitis in 4 cases (8%), and diarrhea in 11 cases (22%). The ORR was 18%; 2% of patients had a complete response (CR), 16% a partial response (PR) and 74% achieved stable disease (SD). All CRs and all PRs as well as 92% of SDs had a duration ≥6 months. The clinical benefit (CR+PR+SD) was 92%. At a median follow-up of 277 days, median time to progression and overall survival were not reached.
The everolimus-octreotide LAR combination was active and well tolerated in these previously treated patients with advanced NETs, suggesting a possible role as first-line treatment in patients with NET. Cancer 2014;120:2457–2463. © 2014 American Cancer Society.